β-Lactamase-producing bacteria in mixed infections  by Brook, I.
REVIEW 10.1111/j.1469-0691.2004.00962.x
b-Lactamase-producing bacteria in mixed infections
I. Brook
Department of Pediatrics, Georgetown University School of Medicine, Washington DC, USA
b-Lactamase-producing bacteria (BLPB) can play an important role in polymicrobial infections. They can
have a direct pathogenic impact in causing infections, as well as an indirect effect through their ability to
produce the b-lactamase. BLPB may not only survive penicillin therapy themselves, but can also protect
other penicillin-susceptible bacteria from penicillin by releasing free b-lactamase into their immediate
environment. This phenomenon occurs in upper respiratory tract, skin, soft tissue, surgical and other
infections. The in-vitro and in-vivo clinical evidence supporting the role of BLPB in the increasing failure
of penicillin to resolve such infections, and the implications of this phenomenon for the management of
infections, are discussed.
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INTRODUCTION
Penicillins have been the agents of choice for the
treatment of a wide range of bacterial infections.
However, increased resistance to these drugs has
been noted during the last 50 years. In addition to
bacteria known for many years to exhibit resist-
ance to penicillin, such as Staphylococcus aureus
and members of the Enterobacteriaceae, other
previously susceptible organisms have become
increasingly resistant because of a range of resist-
ance mechanisms, one of which is an ability to
produce the enzyme b-lactamase. These resistant
organisms include aerobic and facultative bacteria
such as Haemophilus influenzae [1] and Moraxella
catarrhalis [2], as well as anaerobic Gram-negative
bacilli (e.g., members of the Bacteroides fragilis
group, pigmented Prevotella and Porphyromonas
spp., Prevotella bivia, Prevotella disiens and Fuso-
bacterium spp.) [3].
b-Lactamase-producing bacteria (BLPB) may
have an important clinical role in infections.
These organisms can be pathogenic in that they
can cause an infection, but may also have an
indirect effect through their ability to produce
b-lactamase. BLPB may not only survive penicil-
lin therapy, but may also protect other penicillin-
susceptible bacteria from penicillins by releasing
free b-lactamase into their environment [4]. This
review highlights the importance of BLPB in
different infections. The in-vitro and in-vivo
clinical evidence supporting the role of these
organisms in the increased failure of penicillin to
resolve infections, and the implications of this
phenomenon for the management of infections,
are discussed.
EVIDENCE FOR INDIRECT
PATHOGENICITY OF BLPB
The production of b-lactamase by aerobic and
anaerobic bacteria is an important mechanism of
indirect pathogenicity that is especially apparent
in polymicrobial infection. Not only are organ-
isms producing b-lactamase protected from the
activity of penicillins, but other penicillin-sus-
ceptible organisms can also be shielded. This
protection can occur when b-lactamase is secreted
into infected tissues or abscess fluid in sufficient
quantities to break the b-lactam structural ring of
penicillin before the susceptible bacteria are
killed. Several clinical and laboratory studies that
illustrate this hypothesis are described below.
In-vivo and in-vitro studies
Animal studies have demonstrated the ability of
b-lactamase to influence polymicrobial infections.
Hackman and Wilkins [5] demonstrated in mice
that penicillin-resistant strains of B. fragilis,
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pigmented Prevotella and Porphyromonas spp., and
Prevotella oralis protected a penicillin-sensitive
strain of Fusobacterium necrophorum from penicil-
lin therapy. Brook et al. [6] used a subcutaneous
abscess model in mice to demonstrate protection
of group A b-haemolytic streptococci (GABHS)
from penicillin by B. fragilis and Prevotella mela-
ninogenica. Clindamycin, or the combination of
penicillin and clavulanic acid (a b-lactamase
inhibitor), which are active against both GABHS
and anaerobic Gram-negative bacilli, were effect-
ive in eradicating the infection. Similarly,
b-lactamase-producing facultative bacteria pro-
tected a penicillin-susceptible strain of Prev. mel-
aninogenica from penicillin [7].
In-vitro studies have also illustrated this phe-
nomenon. A 200-fold increase in resistance to
penicillin of GABHS was found when a strain was
co-inoculated with S. aureus [8]. An increase in
resistance was also demonstrated when GABHS
were grown with Haemophilus parainfluenzae [9].
When they were mixed with cultures of B. fragilis,
the resistance of GABHS to penicillin increased
8500-fold [10].
b-Lactamase in clinical infections
Several studies have demonstrated the activity of
b-lactamase in polymicrobial infections. De Lou-
vois and Hurley [11] showed degradation of
penicillin, ampicillin and cephaloridine by puru-
lent exudates obtained from four of 22 patients
with abscesses. Studies by Masuda and Tomioka
[12] demonstrated possible b-lactamase activity in
empyema fluid. Most infections were polymicro-
bial and involved both Klebsiella pneumoniae and
Pseudomonas aeruginosa. O’Keefe et al. [13]
observed inactivation of penicillin G in an experi-
mental model of B. fragilis infection in the rabbit
peritoneum. These studies suggest that local
infection with BLPB may modify the penicillin
content of abscess fluid by enzymic degradation.
The presence of b-lactamase in clinical speci-
mens has also been reported. Bryant et al. [14]
studied b-lactamase activity in samples of pus
obtained from 12 patients with polymicrobial
intra-abdominal abscess or polymicrobial empy-
ema. Using the chromogenic cephalosporin nitr-
ocefin, these investigators were able to show
strong enzyme activity in four of 11 abscess fluid
samples. Boughton [15] studied cerebrospinal
fluid specimens with the use of nitrocefin and
was able to detect enzyme activity in all five
specimens that contained b-lactamase-producing
H. influenzae. However, no b-lactamase was detec-
ted in 33 specimens that contained non-b-lacta-
mase-producing H. influenzae or in 234 sterile
specimens.
A separate study [16] investigated the presence
of BLPB and b-lactamase activity in 109 abscesses.
One hundred isolates of BLPB were recovered
from 88 (77%) specimens. These included all 28
isolated members of the B. fragilis group, 18 of 30
pigmented Prevotella and Porphyromonas spp.,
42 of 43 S. aureus isolates and 11 of 14 Escherichia
coli isolates. b-Lactamase activity was detected in
40 (55%) of the purulent specimens with the
nitrocefin method.
With the same method, b-lactamase activity
was detected in 46 (55%) of 88 ear aspirates that
contained BLPB [16]. It was also possible to detect
b-lactamase in ear aspirates from 30 (79%) of 38
children with chronic otitis media [17], and
b-lactamase was detected in 17 (89%) of 19 ear
aspirates from children with acute otitis media
who failed to respond to therapy with amoxycillin
[18]. Similar results were obtained with aspirates
of ten acutely and 13 chronically inflamed max-
illary sinuses [19]. The predominant organisms
isolated in cases of acute sinusitis were Strepto-
coccus pneumoniae, H. influenzae and M. catarrhalis,
while those found in cases of chronic sinusitis
were Prevotella, Fusobacterium and Peptostreptococ-
cus spp. Four BLPB were isolated from four (40%)
specimens obtained from acutely inflamed
sinuses, and 14 BLPB were recovered from ten
(77%) chronically inflamed sinuses. The predom-
inant species of BLPB involved in acute sinusitis
were H. influenzae and M. catarrhalis, while those
involved in chronic sinusitis were S. aureus,
Prevotella spp., Fusobacterium spp. and B. fragilis.
b-Lactamase activity was detected in 12 (three in
acute and nine in chronic sinusitis) of the
14 aspirates that contained BLPB (Table 1). The
isolation of penicillin-susceptible bacteria mixed
with BLPB from patients who have failed to
respond to penicillin or cephalosporin therapy
suggests an ability of BLPB to protect a penicillin-
susceptible or cephalosporin-susceptible organ-
ism from the activity of these drugs.
The recovery of BLPB from the oropharynx of
patients with upper respiratory tract infections
(URTIs) seems to be increasing. These organisms
are S. aureus, H. influenzae, M. catarrhalis and
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anaerobic Gram-negative bacteria, and their
emergence seems to be associated with penicillin
therapy.
Our own laboratory investigated the monthly
changes in the rate of recovery of aerobic and
anaerobic penicillin-resistant bacteria in the oro-
pharynx of children [20]. Each month, over a
period of 1 year, the first 30 children who pre-
sented with URTI were studied. The highest
incidence of aerobic and anaerobic BLPB, and
the highest number of patients with BLPB, were
recorded in April (60% of patients), and the
lowest were in September (13% of patients). A
gradual increase in the incidence of BLPB and
penicillin-resistant Strep. pneumoniae occurred
from September to April, and a slow decline from
April to August. These changes correlated di-
rectly with the use of b-lactam antibiotics. The
study was repeated during the following year,
with similar results. The crowding that is more
common in the winter might also have contribu-
ted to the spread of BLPB. Monitoring local
seasonal variations in the rate of isolation of
BLPB may be helpful in the empirical choice of
antimicrobial agents and their judicious use may
control the increase in the incidence of BLPB.
Clinical studies
Selection of BLPB may account for many of the
clinical failures that occur despite penicillin ther-
apy. Heimdahl et al. [21] described five adults
who failed to respond to penicillin therapy in
conjunction with the isolation of anaerobic BLPB.
A study of 185 children with orofacial and
respiratory infections who failed to respond to
penicillin therapy recovered BLPB from 75 (40%)
children [22], with the most frequently isolated
species of BLPB being S. aureus, pigmented
Prevotella and Porphyromonas spp., members of
the B. fragilis group and Prev. oralis. An increased
failure of pelvic inflammatory disease to respond
to b-lactamase-susceptible penicillins has also
been noticed, and these agents are no longer
recommended for treating this infection. Failure
to respond has been reported for up to 33% of
patients [23], and an increased frequency of
abscess formation has been observed [24]. Ther-
apy with penicillin, either alone or in conjunction
with an aminoglycoside or tetracycline, failed to
resolve 15–25% of cases [25]. This increased
failure rate may be a consequence of the increased
resistance to penicillin of anaerobic Gram-negat-
ive bacilli and Neisseria gonorrhoeae, as well as that
of the Enterobacteriaceae involved in pelvic
inflammatory disease.
The URTI in which the phenomenon of indirect
pathogenicity has been studied most thoroughly
is recurrent tonsillitis caused by GABHS. Penicil-
lin was long considered to be the drug of choice
for the treatment of most URTIs because of the
susceptibility of most oral pathogens. However,
the growing resistance of oral pathogens has now
limited the use of this drug. The frequently
reported inability of penicillin to eradicate GAB-
HS is of concern. A clinical study [26] demon-
strated the persistence of GABHS in the pharynx,
despite treatment with intramuscular penicillin, in
21% of patients after the first course of therapy,
and in 83% of the patients who were re-treated.
Two randomised, single-blind, multicentre anti-
biotic efficacy trials in children illustrated that the
recommended doses failed to eradicate GABHS in
acute-onset pharyngitis from 35% of patients
treated with oral penicillin V and 37% of those
receiving intramuscular penicillin [27].
Various theories have been offered to explain
these failures to eradicate. One explanation is that
repeated penicillin administration results in a
shift in the oral microflora, with selection of
b-lactamase-producing strains of Haemophilus
spp., S. aureus, M. catarrhalis and anaerobic
Gram-negative bacilli [8,9,21,22,28,29]. It is poss-
ible that these BLPB can protect GABHS from
penicillin by inactivation of the antibiotic.
Clinical evidence supporting the ability of
BLPB to protect penicillin-susceptible pathogens
was first reported in 1963 [8]. Subsequently,
Knudsin and Miller [30] found a significantly
higher carrier rate of penicillin-resistant S. aureus
in patients who had failed to respond to penicillin
Table 1. Bacteria isolated from chronic sinusitis aspirates
Organism detected
Patient no.
1 2 3 4
Staphylococcus aureus (BL+) + +
Streptococcus pneumoniae +
Peptostreptococcus spp. + +
Propionibacterium acnes +
Fusobacterium spp. (BL+) + +
Fusobacterium spp. (BL–) + +
Prevotella spp. (BL+) +
Prevotella spp. (BL–) + + +
Bacteroides fragilis group (BL+) + +
b-Lactamase activity in pus + + + +
BL+, b-lactamase-producing bacteria.
Data taken from Brook et al. [19].
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treatment than in those in whom treatment was
successful. In contrast, Quie et al. [31], who did
not use methods for detection of anaerobic BLPB,
found no correlation between the presence of
b-lactamase-producing S. aureus before therapy,
or at follow-up, with penicillin treatment failure
or success. Clinical studies have suggested that
H. parainfluenzae [9] and M. catarrhalis [32] may
also have a role in the success or failure of
penicillin treatment.
The role of anaerobic BLPB in the persistence
of GABHS in tonsils was suggested by Brook
et al. [33–35], who studied core tonsillar cultures
of 50 children suffering from recurrent tonsillitis.
One or two strains of aerobic and ⁄ or anaerobic
BLPB were recovered from 74% of the tonsils.
The anaerobic BLPB included isolates of the
B. fragilis group, pigmented Prevotella and Por-
phyromonas spp., and Prev. oralis, while the
aerobic bacteria were S. aureus, Haemophilus
spp. and M. catarrhalis. These observations were
confirmed by Reilly et al. [36], Chagollan et al.
[37] and Tuner and Nord [38]. Assays of the free
enzyme in tissues demonstrated its presence in
33 (85%) of 39 tonsils that harboured BLPB,
while the enzyme was absent in the 11 tonsils
without BLPB [35].
Studies by Tuner and Nord [39] and Brook and
Gober [40] have demonstrated the rapid emer-
gence of BLPB following penicillin therapy. Tuner
and Nord [39] studied the emergence of BLPB in
the oropharynx of ten healthy volunteers treated
with penicillin for 10 days. A significant increase
in the number of b-lactamase-producing isolates
of Bacteroides spp., Fusobacterum nucleatum and
S. aureus was observed. b-Lactamase activity in
saliva increased significantly in parallel with the
increase in BLPB. Brook and Gober [40] isolated
BLPB from three (14%) of 21 children before
penicillin therapy, and from ten (48%) following
one course of penicillin. The organisms isolated
were pigmented Prevotella and Porphyromonas
spp., S. aureus, M. catarrhalis and H. influenzae. A
separate study [41] of 26 children who received
therapy with penicillin for 7 days found that 11%
harboured BLPB in their oropharyngeal flora
before therapy, increasing to 45% at the conclu-
sion of therapy, with an incidence of 27% after a
further 3 months. These data suggest that emer-
gence of BLPB occurs rapidly in the upper
respiratory tract following penicillin therapy.
These organisms were also isolated from house-
hold contacts of children treated repeatedly with
penicillin, suggesting possible transfer within a
family.
Certain groups of children are at greater risk of
developing penicillin-resistant flora. Administra-
tion of chemoprophylaxis with amoxycillin for the
prevention of recurrent otitis media has become a
common practice in recent years. Although pro-
phylaxis with amoxycillin has been shown to
prevent ear infections in susceptible patients,
patients receiving the drug are at risk of selecting
BLPB in their nasopharynx. In a study [42] of the
effect of amoxycillin chemoprophylaxis on the
recovery rate of penicillin-resistant nasopharyn-
geal aerobic and anaerobic bacteria, the rate of
recovery of BLPB from the oropharynx of 20
children with otitis media who received amoxycil-
lin or sulfisoxazole chemoprophylaxis for
4–6 months was investigated monthly over a
9-month period. The major BLPB isolated were
H. influenzae, M. catarrhalis, S aureus, pigmented
Prevotella and Porphyromonas spp., and Fusobacteri-
um spp. The overall recovery rate of BLPB, as well
as penicillin-resistant Strep. pneumoniae, increased
following initiation of amoxycillin chemoprophy-
laxis. Before therapy, six isolates of BLPB were
recovered from four (20%) children. The number
of BLPB increased gradually until all patients were
colonised after receiving prophylaxis for
5 months. Following discontinuation of prophy-
laxis, only three (15%) children were colonised
with BLPB after 4–6 months. No change occurred
in the recovery of BLPB from those children
receiving sulfisoxazole. These data illustrate the
shift towards penicillin resistance in oropharyn-
geal flora during amoxycillin chemoprophylaxis.
An association has been noted between the
presence of BLPB before treatment of acute
tonsillitis caused by GABHS, and the outcome of
10-day oral penicillin therapy [43]. Of 98 children
with acute tonsillitis caused by GABHS, 36 failed
to respond to therapy (Table 2). Before therapy,
18 isolates of BLPB were obtained from 16 (26%)
of those cured, while, following therapy, 30 such
organisms were recovered from 19 (31%) of these
children. In contrast, before therapy, 40 isolates of
BLPB were recovered from 25 (69%) of the
children who failed to respond, while, following
therapy, 62 such organisms were obtained from
31 (86%) of the children in that group. Roos et al.
[44] showed that high levels of b-lactamase in
saliva may reflect colonisation with many strains
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of BLPB. These investigators demonstrated that
patients with recurrent tonsillitis caused by GAB-
HS had detectable amounts of b-lactamase in their
saliva compared to patients with uncomplicated
courses of tonsillitis.
Previous antimicrobial therapy can select for
resistant bacterial strains, that may persist in the
nasopharynx, to re-emerge in new infections. In
this context, an evaluation was made [45] of the
antimicrobial susceptibility of pathogens isolated
from the middle ear of 22 children with otitis
media, and from the sinus aspirates of 20 patients
with maxillary sinusitis who failed to respond to
antimicrobial therapy. Resistance to the antimi-
crobial agents used was found in 23 (49%) of the
47 isolates found in 20 (48%) of the patients.
These included ten (67%) of 15 isolates of Strep.
pneumoniae, four (29%) of 14 isolates of H. influen-
zae, four (57%) of seven isolates of S. aureus, and
five (83%) of six isolates of M. catarrhalis. A sta-
tistically significant higher recovery of resistant
organisms was observed from patients treated
2–6 months previously, and from those patients
with sinusitis who smoked.
The data presented above illustrate the increas-
ing role of BLPB in mixed infections, and also
demonstrate the rapidity with which BLPB can
appear in patients and spread to other household
members.
THERAPEUTIC IMPLICATIONS OF
INDIRECT PATHOGENICITY
The presence of BLPB in mixed infection warrants
administration of drugs that will be effective in
eradication of BLPB as well as other pathogens.
The high failure rate of penicillin therapy associ-
ated with the recovery of BLPB from a growing
number of cases of mixed aerobic–anaerobic
infections highlights the importance of this thera-
peutic approach [21,22]. One infection for which
this therapeutic approach has been successful is
recurrent tonsillitis [26,46–59]. Antimicrobial
agents active against BLPB as well as GABHS
were effective in the eradication of this infection.
Smith et al. [26] demonstrated the superiority of
dicloxacillin therapy (50% success rate) compared
to penicillin (17% success rate) in eradicating
recurrent tonsillitis caused by GABHS. Several
studies have demonstrated the efficacy of linco-
mycin [46–49] and clindamycin [50–55], and of the
combination of penicillin plus rifampicin over
penicillin alone [57], and of clindamycin over
penicillin plus rifampicin [58]. The superiority of
these drugs compared to penicillin is associated
with their efficacy against GABHS, as well as
Bacteroides spp. and S. aureus.
Amoxycillin–clavulanate has also been found
to be superior to penicillin for therapy of recur-
rent tonsillitis [59]. GABHS were eradicated from
14 (70%) of 20 patients treated with penicillin,
compared with 100% of those treated with
amoxycillin–clavulanate (p < 0.001). In a 1-year
follow-up, 11 of 19 patients treated with penicillin
and two of 18 treated with amoxycillin–clavula-
nate had recurrent tonsillitis caused by GABHS
(p < 0.005). The addition of clavulanic acid as a
b-lactamase inhibitor enables amoxycillin to erad-
icate the BLPB.
Brook and Hirokawa [54] compared penicillin
to erythromycin and clindamycin in a double-
blind study. Erythromycin was chosen for its
effectiveness against S. aureus and GABHS, while
clindamycin was chosen for its effectiveness
against S. aureus, anaerobic Gram-negative bacilli
and GABHS (Table 3). With penicillin therapy,
there were only two cures out of 15, compared
with six out of 15 for erythromycin, and 14 out of
15 with clindamycin. Four patients who received
penicillin, and two who received erythromycin,
required a tonsillectomy, while none were
Table 2. b-Lactamase-producing organisms isolated from
the tonsillar cultures of 98 children with tonsillitis caused
by group A streptococci (GABHS)
Organisms
Before penicillin
therapy
After penicillin
therapy for 10 days
Group A
(62 patients)
Group B
(36 patients)
Group A
(62 patients)
Group B
(36 patients)
Aerobic and
facultative
6 20 11 30
Anaerobic 12 20 19 32
Total 18 40 30 62
Group A: children who responded to penicillin therapy with eradication of GABHS.
Group B: children who did not respond to penicillin therapy and in whom GABHS
persisted in their tonsils.
Data from Brook [43].
Table 3. Results of a double-blind antibiotic comparison
study involving 45 patients suffering from recurrent
tonsillitis
Antibiotic Clinical cures Tonsillectomies
Penicillin 2 ⁄ 15 4 ⁄ 15
Erythromycin 6 ⁄ 15 2 ⁄ 15
Clindamycin 14 ⁄ 15 0 ⁄ 15
Data from Brook and Hirokawa [54].
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required in the clindamycin group. Fifty-three
patients who failed to respond to a 10-day course
of phenoxymethyl penicillin for pharyngo-tonsil-
litis caused by GABHS were assigned randomly to
continued treatment with penicillin or to treat-
ment with clindamycin. In the first 3-month
period, 15 of 22 patients in the penicillin group
yielded one or more positive cultures for GABHS,
all of the same T-type as in the original throat
culture, compared to three of 26 patients in the
clindamycin group (p < 0.001). All three cases in
the clindamycin group were associated with a new
T-type and were therefore cases of reinfection.
BLPB colonise > 83% of the adenoids of chil-
dren with chronic adeno-tonsillitis [60]. The pres-
ence of BLPB within the core of the adenoids may
explain the persistence of many pathogens, inclu-
ding Strep. pneumoniae, as they may be shielded
from the activity of penicillins. The effect on the
adenoid bacterial flora of therapy for 10 days with
amoxycillin, amoxycillin–clavulanate [61] or clin-
damycin [62] before adenoidectomy for recurrent
otitis media has been studied. The total numbers
of isolates and bacteria/g tissue were lower in
those treated with any one of the antibiotics.
However, the numbers of potential pathogens
and BLPB were lower in those treated with
amoxycillin–clavulanate and clindamycin than
in those treated with amoxycillin and in controls
(p < 0.001).
A similar study evaluated the effects of
amoxycillin–clavulanate or amoxycillin therapy
on the nasopharyngeal flora of children with
acute otitis media [63]. Nasopharyngeal cultures
for aerobic and anaerobic bacteria were taken
before antimicrobial therapy, and 2–4 days after
completion of therapy, from 25 patients treated
with either antibiotic. After therapy, 16 (64%) of
the 25 patients treated with amoxycillin, and 23
(92%) of the 25 patients treated with amoxycillin–
clavulanate, were considered to be clinically
cured. Polymicrobial aerobic–anaerobic flora were
present in all instances. Significant reductions in
the numbers of both aerobic and anaerobic iso-
lates occurred after therapy in those treated with
amoxycillin (177 isolates vs. 133; p < 0.005) and
amoxycillin–clavulanate (172 isolates vs. 60;
p < 0.001). However, the number of all isolates
recovered after therapy from patients treated with
amoxycillin–clavulanate was significantly lower
(60 isolates) than the number isolated from those
treated with amoxycillin (133 isolates; p < 0.001).
The recovery of aerobic pathogens (e.g., Strep.
pneumoniae, S. aureus, GABHS, Haemophilus spp.
and M. catarrhalis) and penicillin-resistant bacteria
was lower after therapy in the amoxycillin–cla-
vulanate group than in the amoxycillin group
(p < 0.005). This study illustrates the greater
ability of amoxycillin–clavulanate, compared with
amoxycillin, to reduce the number of potential
nasopharyngeal pathogens and penicillin-resist-
ant bacteria in children with acute otitis media.
The superiority of amoxycillin–clavulanate and
clindamycin over amoxycillin in eradicating peni-
cillin-susceptible pathogens such as Strep. pneu-
moniae and GABHS may be associated with their
activity against aerobic and anaerobic BLPB. The
elimination of potentially pathogenic and non-
pathogenic BLPB may be beneficial, as these
organisms might ‘shield’ penicillin-susceptible
pathogens from penicillins. This phenomenon
might explain the survival of penicillin-suscept-
ible bacteria, such as Strep. pneumoniae, in children
treated with amoxycillin.
Two studies have compared the efficacy of
clindamycin with that of penicillin for the therapy
of lung abscesses [64,65]. It was suggested that the
observed superiority of clindamycin over penicil-
lin was associated with its ability to eradicate the
b-lactamase-producing anaerobic Gram-negative
bacilli present in lung abscesses.
A retrospective study illustrated the superiority
of antimicrobial agents effective against b-lacta-
mase-producing anaerobic bacteria for the ther-
apy of aspiration- or tracheostomy-associated
pneumonia in 57 children [66]. The antimicrobial
agents used were either ticarcillin–clavulanate or
clindamycin, both of which are effective against
penicillin-resistant anaerobic bacteria, or ceftriax-
one, which is less effective against these organ-
isms. Among patients with aspiration pneumonia,
eight (89%) of nine who received ticarcillin–
clavulanate, ten (91%) of 11 who received clinda-
mycin with or without ceftazidime, and seven
(50%) of 14 who received ceftriaxone, had a
satisfactory clinical and microbiological response
(p < 0.05). Among patients with tracheostomy-
associated pneumonia, five (83%) of six who
received ticarcillin–clavulanate, all seven (100%)
who received clindamycin with or without ceft-
azidime, and four (40%) of ten who were treated
with ceftriaxone, responded to therapy (p < 0.05).
The duration of fever was longer in those who
received ceftriaxone.
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CONCLUSIONS
In polymicrobial infections that involve BLPB,
therapy should also be directed against these
bacteria. This can be achieved either by the
addition of agents such as an aminoglycoside or
a third-generation cephalosporin directed against
aerobic Gram-negative bacteria, or by the admin-
istration of agents with a wide spectrum of
activity, such as a carbapenem or the combination
of a penicillin and a b-lactamase inhibitor (e.g.,
ticarcillin–clavulanic acid, piperacillin–tazobac-
tam or ampicillin–sulbactam). Further studies
are needed to explore and ascertain the efficacy
of these therapeutic modalities for the eradication
of infections evolving BLPB.
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